Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $18.30 Average Price Target from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $17.40.

Several brokerages recently weighed in on YMAB. Truist Financial cut their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. HC Wainwright decreased their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday, March 21st. Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research note on Tuesday. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Finally, Wedbush reaffirmed an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 22.50% of the company's stock.

Institutional Trading of Y-mAbs Therapeutics

Large investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new stake in Y-mAbs Therapeutics during the 4th quarter valued at approximately $46,000. ProShare Advisors LLC bought a new position in Y-mAbs Therapeutics during the fourth quarter valued at about $99,000. Exchange Traded Concepts LLC raised its holdings in Y-mAbs Therapeutics by 107.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock valued at $119,000 after acquiring an additional 13,890 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after purchasing an additional 4,163 shares during the period. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Stock Performance

YMAB stock traded down $0.18 on Friday, reaching $3.94. The company had a trading volume of 41,910 shares, compared to its average volume of 327,390. The company's fifty day moving average is $4.95 and its 200 day moving average is $8.32. The company has a market cap of $177.98 million, a P/E ratio of -7.34 and a beta of 0.71. Y-mAbs Therapeutics has a 1 year low of $3.84 and a 1 year high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the business earned ($0.02) earnings per share. On average, sell-side analysts predict that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.